GeoVax Labs, Inc., a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, and BravoVax, a vaccine developer in Wuhan, China, have signed a Letter of Intent to jointly develop a vaccine against the coronavirus (known as 2019-nCoV). GeoVax will use its MVA-VLP vaccine platform to design and construct the vaccine candidate using genetic sequences from the ongoing coronavirus outbreak originating in Wuhan, China. BravoVax will provide further...